A paper published on Zenodo ( https://c212.net/c/link/?t=0&l=en&o=2959644-1&h=1564169084&u=https%3A%2F%2Fzenodo.org%2F&a=Zenodo ) (DOI 10.5281/zenodo.4119263) by Dr. Steven Quay, M.D., PhD., head of two COVID-19 therapeutic programs at Atossa Therapeutics, Inc. (NASDAQ: ATOS), illuminates new scientific observations and conclusions documenting that the SARS-CoV-2 pandemic began at the General Hospital of Central Theater Command of People's Liberation Army (PLA Hospital) in Wuhan, China, located at 627 Wulon Road, Wuchang District, Wuhan. International biospecimen data repositories indicate as early as December 10, 2019 COVID patient records were being created by PLA personnel, weeks before the Chinese government informed the WHO of the pandemic. Video - https://mma.prnewswire.com/media/1319041/COVID_19_New_Origins_10_28_20.mp4 The paper documents four patients from the PLA Hospital that have the earliest genetic signature of direct human-to-human coronavirus transmission. It also includes the patient whose coronavirus is genetically closest to a bat virus from the Wuhan Institute of Virology (WIV) that WIV scientists call "the closest relative of 2019-nCoV." The PLA Hospital is three km from WIV and both are located on Line 2 of the Wuhan Metro System. The paper documents an analysis of the hospitals where the earliest COVID patients were seen, between December 1, 2019 to early January, and shows that all these hospitals were also located on the Metro Line 2. This is the first paper in the world to observe that Line 2 is uniquely positioned to have been the worldwide human-to-human COVID pandemic conduit as it carries five percent of the population of Wuhan every day, allowing rapid spread throughout Wuhan and the entire Hubei Province; it includes the high-speed rail station, allowing rapid spread throughout China; and it terminates at the international airport station, allowing rapid spread throughout the world. Line 2 also services the Hunan Seafood Market, previously suggested to be associated with the origin of the pandemic. About Steven Quay, M.D., PhD, Head of Two COVID-19 Therapeutic Programs (AT-201) ( https://c212.net/c/link/?t=0&l=en&o=2959644-1&h=2755652726&u=https%3A%2F%2Fatossatherapeutics.com%2Fabout-us%2F&a=AT-201 ) and (AT-301 Nasal Spray) (https://c212.net/c/link/?t=0&l=en&o=2959644-1&h=2113167730&u=https%3A%2F%2Fwww. globenewswire.com%2Fnews-release%2F2020%2F08%2F03%2F2071773%2F0%2Fen%2FAtossa-Th erapeutics-Receives-Approval-to-Open-Clinical-Study-of-AT-301-Nasal-Spray-Being- Developed-to-Treat-COVID-19.html&a=AT-301+Nasal+Spray ) Dr. Steven Quay has 300+ published contributions to medicine and has been cited over 9,900 times, placing him in the top 1% of scientists worldwide. He holds 87 US patents and has invented seven FDA-approved pharmaceuticals which have helped over 80 million people. He is the author of the best-selling book on surviving the pandemic, Stay Safe: A Physician's Guide to Survive Coronavirus. He is the CEO of Atossa Therapeutics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics for treating breast cancer and COVID-19. He received his M.D. and Ph.D. from The University of Michigan, was a postdoctoral fellow in the Chemistry Department at MIT with Nobel Laureate H. Gobind Khorana, a resident at the Harvard-MGH Hospital, and spent almost a decade on the faculty of Stanford University School of Medicine. A TEDx talk he delivered on breast cancer prevention has been viewed over 220,000 times. For more information, visit www.DrQuay.com Public Relations Contact: Dunn Pellier Media| t: +1 323.481.2307 11620 Wilshire Blvd., 9th Floor, Los Angeles, CA 90025 natalie@dunnpelliermedia.com nicole@dunnpelliermedia.com SOURCE: Dr. Steven Quay